[Carcinochemotherapy in pediatric surgery (author's transl)].

G. Hollmann,F. Lampert

DOI: https://doi.org/10.1007/BF01257495

1975-11-01

Abstract:

What problem does this paper attempt to address?

Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron

Minfeng Huo,Zhimin Tang,Liying Wang,Linlin Zhang,Haiyan Guo,Yu Chen,Ping Gu,Jianlin Shi

DOI: https://doi.org/10.1038/s41467-022-35503-y

IF: 16.6

2022-12-15

Nature Communications

Abstract:Abstract Distressing and lethal cardiotoxicity is one of the major severe side effects of using anthracycline drugs such as doxorubicin for cancer chemotherapy. The currently available strategy to counteract these side effects relies on the administration of cardioprotective agents such as Dexrazoxane, which unfortunately has unsatisfactory efficacy and produces secondary myelosuppression. In the present work, aiming to target the characteristic ferrous iron overload in the doxorubicin-contaminated cardiac microenvironment, a biocompatible nanomedicine prepared by the polyvinylpyrrolidone-directed assembly of magnesium hexacyanoferrate nanocatalysts is designed and constructed for highly efficient intracellular ferrous ion capture and antioxidation. The synthesized magnesium hexacyanoferrate nanocatalysts display prominent superoxide radical dismutation and catalytic H 2 O 2 decomposition activities to eliminate cytotoxic radical species. Excellent in vitro and in vivo cardioprotection from these magnesium hexacyanoferrate nanocatalysts are demonstrated, and the underlying intracellular ferrous ion traffic regulation mechanism has been explored in detail. The marked cardioprotective effect and biocompatibility render these magnesium hexacyanoferrate nanocatalysts to be highly promising and clinically transformable cardioprotective agents that can be employed during cancer treatment.

multidisciplinary sciences
Cardioprotective Effects of Glycyrrhiza Uralensis Extract Against Doxorubicin-Induced Toxicity.

Ling Zhang,Yinxin Yang,Lingyan Yu,Yi Wang,Li Liu,Xiaohui Fan

DOI: https://doi.org/10.1177/1091581810393033

2011-01-01

International Journal of Toxicology

Abstract:The purpose of the present study was to investigate the cardioprotective effects of Glycyrrhiza uralensis extract (GUE) against doxorubicin (DOX)-induced cardiotoxicity. Imprinting control region (ICR) mice were treated with saline, DOX (20 mg/kg intraperitoneal [ip] for once), GUE (100 mg/kg intragastric [ig] for 8 days), co-treatments with DOX and GUE (100 mg/kg ig for 8 days), and amifostine (100 mg/kg intravenous [iv] for once), respectively. Serum levels of lactate dehydrogenase (LDH) and creatine kinase isoenzyme (CK-MB), glutathione peroxidase (GSH-P(X)) activity, and glutathione (GSH) level in heart tissue were measured. Histopathologic analysis of heart tissue was also performed. Treatment with GUE significantly protected the mice from DOX-induced cardiotoxicity, indicated by decreased levels of serum LDH and CK-MB, improved heart morphology and increased GSH-P(X) activity and GSH level. Additionally, GUE did not compromise the tumor-inhibitory effect of DOX. In conclusion, our studies imply the potentially clinical application of GUE to overcome the cardiotoxicity of doxorubicin.
Ginsenoside Rh2 mitigates doxorubicin-induced cardiotoxicity by inhibiting apoptotic and inflammatory damage and weakening pathological remodelling in breast cancer-bearing mice

Jingang Hou,Yeejin Yun,Changhao Cui,Sunchang Kim

DOI: https://doi.org/10.1111/cpr.13246

Abstract:Objectives: There are presently a few viable ways to reduce cardiotoxicity of doxorubicin (Dox). The combination of chemotherapy agents with natural compounds delivers greater efficacy and reduces adverse effects in recent researches for cancer treatment. Here, we examined the potential effect of ginsenoside Rh2 on a Dox-based regimen in chemotherapy treatment. Materials and methods: Human breast tumour (MDA-MB-231) xenograft nude mice, human cardiac ventricle fibroblasts, and human umbilical vein endothelial cells (HUVEC) were employed in the present study. Histology, immunohistochemistry, immunofluorescence, western blot, antibody array, and RNA-sequencing analyses were utilized to assess the protective effect of Rh2 on cardiotoxicity induced by Dox and the underlying mechanisms. Results: Rh2-reduced cardiotoxicity by inhibiting the cardiac histopathological changes, apoptosis and necrosis, and consequent inflammation. Pathological remodelling was attenuated by reducing fibroblast to myofibroblast transition (FMT) and endothelial-mesenchymal transition (EndMT) in hearts. RNA-sequencing analysis showed that Dox treatment predominantly targets cell cycle and attachment of microtubules and boosted tumour necrosis, chemokine and interferon-gamma production, response to cytokine and chemokine, and T cell activation, whereas Rh2 regulated these effects. Intriguingly, Rh2 also attenuated fibrosis via promoting senescence in myofibroblasts and reversing established myofibroblast differentiation in EndMT. Conclusions: Rh2 regulates multiple pathways in the Dox-provoked heart, proposing a potential candidate for cancer supplement and therapy-associated cardiotoxicity.
Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviating toxicity

Shulei Zhang,Bo Zheng,Yiqi Wei,Yuhao Liu,Lan Yang,Yujiao Qiu,Jing Su,Mingfeng Qiu

DOI: https://doi.org/10.1039/d4bm00159a

2024-03-29

Biomaterials Science

Abstract:Breast cancer, a pervasive malignancy affecting women, demands a diverse treatment approach including chemotherapy, radiotherapy, and surgical interventions. However, the effectiveness of Doxorubicin (DOX), a cornerstone in breast cancer therapy, is limited when used as a monotherapy, and concerns about cardiotoxicity persist. Ginsenoside Rg3, a classic compound of traditional Chinese medicine in Panax ginseng C. A. Mey., possesses diverse pharmacological properties, including cardiovascular protection, immune modulation, and anticancer effects. Ginsenoside Rg3 is considered a promising candidate for enhancing cancer treatment when combined with chemotherapy agents. Nevertheless, the intrinsic challenges of Rg3, such as its poor water solubility and low oral bioavailability, necessitate innovative solutions. Herein, we developed Rg3-PLGA@TMVs via encapsulating Rg3 within PLGA nanoparticles (Rg3-PLGA) and coating them with membranes derived from tumor cell-derived microvesicles (TMVs). Rg3-PLGA@TMVs displayed an array of favorable advantages, including controlled release, prolonged storage stability, high drug loading efficiency and a remarkable ability to activate dendritic cells in vitro. This activation is evident through the augmentation of CD86+CD80+ dendritic cells, along with a reduction in phagocytic activity and acid phosphatase levels. When combined with DOX, the synergistic effect of Rg3-PLGA@TMVs significantly inhibits 4T1 tumor growth and fosters the development of antitumor immunity in tumor-bearing mice. Most notably, this delivery system effectively mitigates the toxic side effects of DOX, particularly those affecting the heart. Overall, Rg3-PLGA@TMVs provides a novel strategy to enhance the efficacy of DOX while simultaneously mitigating its associated toxicities and demonstrates promising potential for the combined chemo-immunotherapy of breast cancer.

materials science, biomaterials
Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity

Tianyu Zhang,Nuannuan Li,Ru Wang,Yiying Sun,Xiaoyan He,Xiaoyan Lu,Liuxiang Chu,Kaoxiang Sun

DOI: https://doi.org/10.1080/10717544.2023.2189118

IF: 6.819

2023-03-16

Drug Delivery

Abstract:Doxorubicin (DOX), a commonly used anti-cancer drug, is limited by its cardiotoxicity and multidrug resistance (MDR) of tumor cells. Epigallocatechin gallate (EGCG), a natural antioxidant component, can effectively reduce the cardiotoxicity of DOX. Meanwhile, EGCG can inhibit the expression of P-glycoprotein (P-gp) and reverse the MDR of tumor cells. In this study, DOX is connected with low molecular weight polyethyleneimine (PEI) via hydrazone bond to get the pH-sensitive PEI-DOX, which is then combined with EGCG to prevent the cardiotoxicity of DOX and reverse the MDR of cancer cells. In addition, folic acid (FA) modified polyethylene glycol (PEG) (PEG-FA) is added to get the targeted system PEI-DOX/EGCG/FA. The MDR reversal and targeting ability of PEI-DOX/EGCG/FA is performed by cytotoxicity and in vivo anti-tumor activity on multidrug resistant MCF-7 cells (MCF-7/ADR). Additionally, we investigate the anti-drug resistant mechanism by Western Blot. The ability of EGCG to reduce DOX cardiotoxicity is confirmed by cardiotoxicity assay. In conclusion, PEI-DOX/EGCG/FA can inhibit the expression of P-gp and reverse the MDR in tumor cells. It also shows the ability of remove oxygen free radicals effectively to prevent the cardiotoxicity of DOX.

pharmacology & pharmacy
Ginsenoside Rg2 Attenuates Doxorubicin-induced Cardiomyocyte Apoptosis via the PI3K/Akt Pathway

Boyong Qiu,Meijiao Mao,Zilin Ma,Bing Deng,Lin Shen,Duan Zhou,Wang Zheng,Yihong Wei

DOI: https://doi.org/10.1007/s43450-022-00261-x

2022-05-09

Revista Brasileira de Farmacognosia

Abstract:Doxorubicin, sold under the brand name Adriamycin among others, is an important drug for cancer therapy; however, its use is limited by its cardiotoxicity. Ginsenoside Rg2 is extracted from Panax ginseng C.A.Mey., Araliaceae, which is believed to have cardioprotective properties. However, to date, there have been no reports on whether ginsenoside Rg2 could protect cardiomyocytes against doxorubicin. In this study, we investigated the action and the underlying mechanisms of cardioprotection of ginsenoside Rg2 upon doxorubicin treatment. Cell counting kit-8 was used to determine cell viability; in addition, terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling staining was used to detect apoptotic cells. Western blotting was used to investigate the relevant pathways. LY294002, a phosphatidylinositol 3-kinase inhibitor, was also used in this study. Ginsenoside Rg2 significantly ( p < 0.01) neutralized cardiomyocyte apoptosis induced by doxorubicin in a dose-dependent manner, but this effect was blocked by LY294002. Furthermore, ginsenoside Rg2 upregulated protein kinase B phosphorylation through the phosphatidylinositol 3-kinase/protein kinase B pathway and inhibited p53 expression. These results suggest that ginsenoside Rg2 could attenuate doxorubicin-induced cardiomyocyte apoptosis via the phosphatidylinositol 3-kinase/protein kinase B pathway.
Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy

Chuying Huang,Yishan Guo,Tuo Li,Guogen Sun,Jinru Yang,Yuqi Wang,Ying Xiang,Li Wang,Min Jin,Jiao Li,Yong Zhou,Bing Han,Rui Huang,Jiao Qiu,Yong Tan,Jiaxing Hu,Yumiao Wei,Bo Wu,Yong Mao,Lingshan Lei,Xiusheng Song,Shuijie Li,Yongsheng Wang,Tao Zhang

DOI: https://doi.org/10.1016/j.redox.2023.103024

IF: 11.4

2024-01-12

Redox Biology

Abstract:Due to the cardiotoxicity of doxorubicin (DOX), its clinical application is limited. Lipid peroxidation caused by excessive ferrous iron is believed to be a key molecular mechanism of DOX-induced cardiomyopathy (DIC). Dexrazoxane (DXZ), an iron chelator, is the only drug approved by the FDA for reducing DIC, but it has many side effects and cannot be used as a preventive drug in clinical practice. Single-nucleus RNA sequencing (snRNA-seq) analysis identified myocardial and epithelial cells that are susceptible to DOX-induced ferroptosis. The glutathione peroxidase 4 (GPX4) activator selenomethione (SeMet) significantly reduced polyunsaturated fatty acids (PUFAs) and oxidized lipid levels in vitro . Consistently, SeMet significantly decreased DOX-induced lipid peroxidation in H9C2 cells and mortality in C57BL/6 mice compared to DXZ, ferrostatin-1, and normal saline. SeMet can effectively reduce serum markers of cardiac injury in C57BL/6 mice and breast cancer patients. Depletion of the GPX4 gene in C57BL/6 mice resulted in an increase in polyunsaturated fatty acid (PUFA) levels and eliminated the protective effect of SeMet against DIC. Notably, SeMet exerted antitumor effects on breast cancer models with DOX while providing cardiac protection for the same animal without detectable toxicities. These findings suggest that pharmacological activation of GPX4 is a valuable and promising strategy for preventing the cardiotoxicity of doxorubicin.

biochemistry & molecular biology
An orally administered bacterial membrane protein nanodrug ameliorates doxorubicin cardiotoxicity through alleviating impaired intestinal barrier

Zhen Li,Junyue Xing,Xiaohan Ma,Wanjun Zhang,Chuan Wang,Yingying Wang,Xinkun Qi,Yanhui Liu,Dongdong Jian,Xiaolei Cheng,Yanjie Zhu,Chao Shi,Yongjun Guo,Huan Zhao,Wei Jiang,Hao Tang

DOI: https://doi.org/10.1016/j.bioactmat.2024.03.027

IF: 18.9

2024-04-26

Bioactive Materials

Abstract:Highlights • Intestinal barrier – a required safeguard against Dox cardiotoxicity. • An orally available, intestinal targeting, and Amuc_1100 assembled nanodrug (HFPA) is developed to successfully alleviate Dox cardiotoxicity. • HFPA reduces Dox cardiotoxicity through improving gut microenvironment as well as cardiac immune homeostasis. The cardiotoxicity caused by Dox chemotherapy represents a significant limitation to its clinical application and is a major cause of late death in patients undergoing chemotherapy. Currently, there are no effective treatments available. Our analysis of 295 clinical samples from 132 chemotherapy patients and 163 individuals undergoing physical examination revealed a strong positive correlation between intestinal barrier injury and the development of cardiotoxicity in chemotherapy patients. We developed a novel orally available and intestinal targeting protein nanodrug by assembling membrane protein Amuc_1100 (obtained from intestinal bacteria Akkermansia muciniphila ), fluorinated polyetherimide, and hyaluronic acid. The protein nanodrug demonstrated favorable stability against hydrolysis compared with free Amuc_1100. The in vivo results demonstrated that the protein nanodrug can alleviate Dox-induced cardiac toxicity by improving gut microbiota, increasing the proportion of short-chain fatty acid-producing bacteria from the Lachnospiraceae family, and further enhancing the levels of butyrate and pentanoic acids, ultimately regulating the homeostasis repair of lymphocytes in the spleen and heart. Therefore, we believe that the integrity of the intestinal barrier plays an important role in the development of chemotherapy-induced cardiotoxicity. Protective interventions targeting the intestinal barrier may hold promise as a general clinical treatment regimen for reducing Dox-induced cardiotoxicity. Graphical abstract Download : Download high-res image (262KB) Download : Download full-size image

engineering, biomedical,materials science, biomaterials
Targeting OGF/OGFR signal to mitigate doxorubicin-induced cardiotoxicity

Xiru Chen,Dongdong Jian,Junyue Xing,Xiaolei Cheng,Chuan Wang,Chenqiu Wang,Jiangpeng Pan,Xinkun Qi,Shixing Wang,Zhen Li,Ying Liu,Liguo Jian,Hao Tang

DOI: https://doi.org/10.1016/j.freeradbiomed.2024.08.005

2024-08-08

Abstract:Enkephalins are reportedly correlated with heart function. However, their regulation in the heart remains unexplored. This study revealed a substantial increase in circulating levels of opioid growth factor (OGF) (also known as methionine enkephalin) and myocardial expression levels of both OGF and its receptor (OGFR) in subjects treated with doxorubicin (Dox). Silencing OGFR through gene knockout or using adeno-associated virus serotype 9 carrying small hairpin RNA effectively alleviated Dox-induced cardiotoxicity (DIC) in mice. Conversely, OGF supplementation exacerbated DIC manifestations, which could be abolished by administration of the OGFR antagonist naltrexone (NTX). Mechanistically, the previously characterized OGF/OGFR/P21 axis was identified to facilitate DIC-related cardiomyocyte apoptosis. Additionally, OGFR was observed to dissociate STAT1 from the promoters of ferritin genes (FTH and FTL), thereby repressing their transcription and exacerbating DIC-related cardiomyocyte ferroptosis. To circumvent the compromised therapeutic effects of Dox on tumors owing to OGFR blockade, SiO2-based modifiable lipid nanoparticles were developed for heart-targeted delivery of NTX. The pretreatment of tumor-bearing mice with the assembled NTX nanodrug successfully provided cardioprotection against Dox toxicity without affecting Dox therapy in tumors. Taken together, this study provides a novel understanding of Dox cardiotoxicity and sheds light on the development of cardioprotectants for patients with tumors receiving Dox treatment.
A Novel Self-Assembly Albumin Nanocarrier for Reducing Doxorubicin-Mediated Cardiotoxicity.

Ahu Yuan,Jinhui Wu,Chenchen Song,Xiaolei Tang,Qian Qiao,Lili Zhao,Guangming Gong,Yiqiao Hu

DOI: https://doi.org/10.1002/jps.23455

IF: 3.8

2013-01-01

Journal of Pharmaceutical Sciences

Abstract:Doxorubicin is an antitumor drug commonly used against a wide spectrum of tumors. However, the clinical application of DOX is restricted by its cardiotoxicity. To reduce the cardiotoxicity, we develop an albumin-based nanocarrier via a new molecular switch method for DOX delivery. Spherically shaped DOX-loaded HSA nanoparticles (NPs-DOX) are prepared with a drug-loading capacity and particle size of 4.3% and 120.1 ± 26 nm, respectively. In vivo studies demonstrate that NPs-DOX is able to preferentially accumulate in tumor and show great tumor inhibition on H22 hepatocellular-carcinoma-bearing mice. As for the toxicity, compared with free DOX, the maximum tolerated dose of NPs-DOX is increased from 10 to over 30 mg/kg, indicating the reduced systematic toxicity. More importantly, the cardiotoxicity induced by NPs-DOX is also significantly reduced because both left ventricular ejection fraction and left ventricular fractional shortening are almost not changed and other cardiotoxicity markers such as serum creatine kinase-MB, lactate dehydrogenase, superoxide dismutase, and malonaldehyde are kept constant. The reduced cardiotoxicity of NPs-DOX is also confirmed by nonhistological changes in the heart tissue. Therefore, such albumin-based nanocarrier can be one of the most promising strategies for the delivery of DOX.
Augmented gastric inhibitory polypeptide and insulin responses to a meal after an increase in carbohydrate (sucrose) intake.

E. Mazzaferri,G. Starich,S. S. St. Jeor

DOI: https://doi.org/10.1210/JCEM-58-4-640

1984-04-01

Abstract:The gastric inhibitory polypeptide (GIP) response to certain stimuli may be exaggerated in patients with obesity and noninsulin-dependent diabetes mellitus. To explore the effects of increased caloric intake and dietary composition on GIP secretion, 20 normal lean volunteers underwent a 4-week ambulatory study. A baseline week (usual diet) was followed by 3 weeks in which the usual diet was supplemented with 45 g fat (diet A), 100 g carbohydrate in the form of sucrose (diet B), or 50 g protein (diet C) for 1 week each. Almost equal numbers of subjects followed sequence ABC, BCA, or CAB in this cross-over study. At the end of the baseline week and each study week, serum glucose, insulin, and GIP were measured in response to a 500-cal liquid test meal. Daily intake of carbohydrate, protein, or fat, as monitored by food records, increased significantly (P less than 0.01) during the appropriate dietary periods, whereas body weight changed slightly, but not significantly, during the 3 study periods. No changes occurred in the total integrated serum glucose concentrations, whereas integrated insulin concentrations changed significantly (P less than 0.05), being 32.5 +/- 3.1 (+/- SEM), 37.2 +/- 4.0, and 30.3 +/- 3.1 microU/ml min-1 during periods A, B, and C, respectively. Insulin secretion was greatest during period B, the carbohydrate week, when insulin concentrations 15-60 min after the test meal were significantly greater (P less than 0.05 to P less than 0.01) than after the baseline period. Total integrated incremental serum GIP concentrations were also significantly different (P less than 0.01) during the 3 study periods, being 1.93 +/- 0.13, 2.53 +/- 0.24, and 1.90 +/- 0.11 ng/ml min-1 during A, B, and C, respectively. Serum GIP was highest during period B (carbohydrate), when average concentrations were significantly higher (P less than 0.01) 15-60 min after the meal compared to those during the baseline study. Similar changes did not occur with the other diets. Thus, GIP and insulin secretion were substantially altered by an acute increase in sucrose intake. The exaggerated GIP response to a meal in some patients with obesity may possibly be the result of adaptation of intestinal GIP cells to diet, particularly one rich in sucrose.
AstragalusPolysaccharide Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the PI3k/Akt and P38mapk Pathways

Yuan Cao,Yuanyuan Ruan,Tao Shen,Xiuqing Huang,Meng Li,Weiwei Yu,Yanhua Zhu,Yong Man,Shu Wang,Jian Li

DOI: https://doi.org/10.1155/2014/674219

2014-01-01

Oxidative Medicine and Cellular Longevity

Abstract:Doxorubicin, a potent chemotherapeutic agent, is associated with acute and chronic cardiotoxicity, which is cumulatively dose-dependent. Astragalus polysaccharide (APS), the extract of Astragalus membranaceus with strong antitumor and antiglomerulonephritis activity, can effectively alleviate inflammation. However, whether APS could ameliorate chemotherapy-induced cardiotoxicity is not understood. Here, we investigated the protective effects of APS on doxorubicin-induced cardiotoxicity and elucidated the underlying mechanisms of the protective effects of APS.We analyzed myocardial injury in cancer patients who underwent doxorubicin chemotherapy and generated a doxorubicin-induced neonatal rat cardiomyocyte injury model and a mouse heart failure model. Echocardiography, reactive oxygen species (ROS) production, TUNEL, DNA laddering, and Western blotting were performed to observe cell survival, oxidative stress, and inflammatory signal pathways in cardiomyocytes.Treatment of patients with the chemotherapeutic drug doxorubicin led to heart dysfunction. Doxorubicin reduced cardiomyocyte viability and induced C57BL/6J mouse heart failure with concurrent elevated ROS generation and apoptosis, which, however, was attenuated by APS treatment. In addition, there was profound inhibition of p38MAPK and activation of Akt after APS treatment.These results demonstrate that APS could suppress oxidative stress and apoptosis, ameliorating doxorubicin-mediated cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways.
Momordica charantia L.-derived exosome-like nanovesicles stabilize p62 expression to ameliorate doxorubicin cardiotoxicity

Cong Ye,Chen Yan,Si-Jia Bian,Xin-Ran Li,Yu Li,Kai-Xuan Wang,Yu-Hua Zhu,Liang Wang,Ying-Chao Wang,Yi-Yuan Wang,Tao-Sheng Li,Su-Hua Qi,Lan Luo

DOI: https://doi.org/10.1186/s12951-024-02705-z

IF: 10.2

2024-08-04

Journal of Nanobiotechnology

Abstract:Doxorubicin (DOX) is a first-line chemotherapeutic drug for various malignancies that causes cardiotoxicity. Plant-derived exosome-like nanovesicles (P-ELNs) are growing as novel therapeutic agents. Here, we investigated the protective effects in DOX cardiotoxicity of ELNs from Momordica charantia L. (MC-ELNs), a medicinal plant with antioxidant activity.

biotechnology & applied microbiology,nanoscience & nanotechnology
Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress

Dan Zhao,Chao Xue,Jiaqi Li,Ke Feng,Peng Zeng,Yuanli Chen,Yajun Duan,Shuang Zhang,Xiaoju Li,Jihong Han,Xiaoxiao Yang

DOI: https://doi.org/10.1016/j.bbrc.2020.09.035

IF: 3.1

2020-12-01

Biochemical and Biophysical Research Communications

Abstract:<p>Doxorubicin (DOX) is an anthracycline derivative and widely used as an anticancer drug. However, the severe cardiotoxicity of DOX limits its application. ADP355 is an adiponectin-based active peptide with anti-liver fibrosis and atherosclerosis properties. It remains unclear the effects and involved mechanisms of ADP355 in DOX-induced cardiotoxicity. C57BL/6J mice were intraperitoneally injected DOX once a week to induce heart failure while receiving ADP355 treatment daily for 4 weeks. At the end of experiment, blood and heart tissues were collected. We found that ADP355 markedly improved DOX-induced cardiac dysfunction and histopathological damage, and decreased serum creatine kinase, lactate dehydrogenase and hydroxybutyrate dehydrogenase levels. The anti-apoptotic activity of ADP355 was indicated by reduction in TUNEL-positive cells and cleaved caspase-3 expression, along with decreased BCL2-associated X protein/B cell lymphoma 2 (BAX/BCL2) levels in heart tissues. Additionally, ADP355 markedly increased DOX-decreased cell viability by reducing BAX/BCL2, but inhibited reactive oxygen species production in H9c2 cells. Mechanistically, ADP355 attenuated expression of DOX-reduced nuclear factor-erythroid 2-related factor 2 (Nrf2) and superoxide dismutase 2, as well as mRNA levels of Nrf2 downstream targets. Furthermore, ADP355 activated sirtuin 2 and its target genes. In conclusion, we demonstrate that ADP355 alleviates DOX-induced cardiotoxicity by inhibiting myocardial apoptosis and oxidative stress through Nrf2 and sirtuin 2 signaling pathways. These findings suggest that ADP355 can be a promising candidate for the treatment of cardiac dysfunction.</p>

biochemistry & molecular biology,biophysics
[Functioning adenomas of the adrenal cortex. Histological and ultrastructural aspects (author's transl)].

B. Antoci,R. Panizzo,M. Romanelli,M. Rocco,G. Floretti

Pathologica

Abstract:
Functional exosomes modified with chitosan effectively alleviate anthracycline-induced cardiotoxicity

Zhiwei Wen,Shuiling Qin,Huajie Huang,Xingle Xia,Wei Zhang,Wei Wu

DOI: https://doi.org/10.1016/j.ijbiomac.2024.134495

Abstract:Anthracyclines belong to a class of anti-tumor antibiotics, and their severe cardiotoxicity significantly limits their clinical use. Exosomes play key roles in intercellular communication, characterized by high biocompatibility and specific tissue and organ homing effects. In this study, doxorubicin, an anthracycline anticancer drug widely used in clinical chemotherapy, was selected as a model drug. To address the significant cardiotoxicity associated with doxorubicin, tumor exosomes are utilized as drug carriers. The homing effect of autologous exosomes enhances drug uptake by tumor cells and reduces cardiotoxicity. To enhance the stability of exosomes, improve therapeutic effectiveness, and reduce toxic side effects, chitosan was utilized to modify the surface of exosomes. Chitosan has a specific anti-tumor effect because it can target the CD44 receptor of tumor stem cells and interact with tumor cells through charge adsorption. Through in vitro cell experiments, in vivo pharmacokinetic experiments, and an in situ ectopic nude mouse tumor model, the study demonstrated that chitosan-modified tumor exosomes significantly alleviated the severe cardiotoxicity of doxorubicin, while also showing remarkable anti-tumor efficacy. This study introduces a novel approach to reduce the adverse side effects of anthracycline chemotherapeutic drugs and presents a highly promising nanocarrier delivery system.
A Cardiac‐Targeting and Anchoring Bimetallic Cluster Nanozyme Alleviates Chemotherapy‐Induced Cardiac Ferroptosis and PANoptosis

Junyue Xing,Xiaohan Ma,Yanan Yu,Yangfan Xiao,Lu Chen,Weining Yuan,Yingying Wang,Keyu Liu,Zhiping Guo,Hao Tang,Kelong Fan,Wei Jiang

DOI: https://doi.org/10.1002/advs.202405597

IF: 15.1

2024-10-29

Advanced Science

Abstract:This study introduces an innovative antioxidant bimetallic cluster nanozyme designed with cardiac‐targeting and anchoring capabilities, effectively mitigating chemotherapy‐induced cardiac ferroptosis and PANoptosis. Doxorubicin (DOX), a potent antineoplastic agent, is commonly associated with cardiotoxicity, necessitating the development of strategies to reduce its adverse effects on cardiac function. Previous research has demonstrated a strong correlation between DOX‐induced cardiotoxicity and the activation of oxidative stress pathways. This work introduces a novel antioxidant therapeutic approach, utilizing libraries of tannic acid and N‐acetyl‐L‐cysteine‐protected bimetallic cluster nanozymes. Through extensive screening for antioxidative enzyme‐like activity, an optimal bimetallic nanozyme (AuRu) is identified that possess remarkable antioxidant characteristics, mimicking catalase‐like enzymes. Theoretical calculations reveal the surface interactions of the prepared nanozymes that simulate the hydrogen peroxide decomposition process, showing that these bimetallic nanozymes readily undergo OH− adsorption and O2 desorption. To enhance cardiac targeting, the atrial natriuretic peptide is conjugated to the AuRu nanozyme. These cardiac‐targeted bimetallic cluster nanozymes, with their anchoring capability, effectively reduce DOX‐induced cardiomyocyte ferroptosis and PANoptosis without compromising tumor treatment efficacy. Thus, the therapeutic approach demonstrates significant reductions in chemotherapy‐induced cardiac cell death and improvements in cardiac function, accompanied by exceptional in vivo biocompatibility and stability. This study presents a promising avenue for preventing chemotherapy‐induced cardiotoxicity, offering potential clinical benefits for cancer patients.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Trophoblast Stem-Cell-Derived Exosomes Alleviate Cardiotoxicity of Doxorubicin via Improving Mfn2-Mediated Mitochondrial Fusion

Junfeng Duan,Xiaoli Liu,Song Shen,Xi Tan,Yi Wang,Lian Wang,Lina Kang,Kun Wang,Zhonghai Wei,Yu Qi,Lei Hu,Biao Xu,Rong Gu

DOI: https://doi.org/10.1007/s12012-022-09774-2

2023-01-08

Cardiovascular Toxicology

Abstract:Doxorubicin (Dox) is an anticancer drug widely used in tumor chemotherapy, but it has the side-effect of cardiotoxicity, which is closely related to mitochondrial damage. Mitochondrial dynamics is a quality control mechanism that usually helps to maintain a healthy mitochondrial pool. Trophoblast stem cell-derived exosomes (TSC-Exos) have been shown to protect cardiomyocytes from DOX-induced cardiotoxicity. To explore whether the cardioprotective role is mediated by the regulation of mitochondrial dynamic mechanism, TSC-Exos were isolated from human trophoblast stem cells by ultracentrifugation and characterized by Western blot and transmission electron microscopy. Cellular experiments of H9c2 cardiomyocytes co-cultured with Dox and TSC-Exos were performed in vitro to determine the levels of reactive oxygen species generation and apoptosis level. An animal model of heart failure was established by intraperitoneal injection of Dox in vivo, therapy mice were received additional intracardiac injection of TSC-Exos, then, the cardiac function, cardiomyocyte apoptosis and mitochondrial fragmentation were ameliorated. Histology assays suggest that Dox caused an increased tendency of mitochondrial fission, which was manifested by a decrease in the average size of mitochondria. By receiving TSC-Exos treatment, this effect was eliminated. In summary, these results suggest that TSC-Exos alleviate DOX-induced cardiotoxicity through antiapoptotic effect and improving mitochondrial fusion with an increase in Mfn2 expression. This study is the first to provide a potential new treatment scheme for the treatment of heart failure from the perspective of the relationship between TSC-Exos and mitochondrial dynamics.

cardiac & cardiovascular systems,toxicology
Screening of renal artery stenosis: assessment with magnetic resonance angiography at 1.0 T.

J. Laissy,M. Benyounes,O. Limot,A. Cinqualbre,H. Benamer,S. Kenouch,M. Henry-Feugeas,B. Falise,S. Chillon,P. Valere,E. Schouman‐Claeys

DOI: https://doi.org/10.1016/S0730-725X(96)00097-5

IF: 3.13

Magnetic Resonance Imaging

Abstract:
Resveratrol, a Polyphenol Phytoalexin, Protects Against Doxorubicin‐induced Cardiotoxicity

Jun Gu,Wei Hu,Dadong Zhang

DOI: https://doi.org/10.1111/jcmm.12633

2015-01-01

Journal of Cellular and Molecular Medicine

Abstract:Doxorubicin is the mainstay of treatment for various haematological malignancies and solid tumours. However, its clinical application may be hampered by dose-dependent cardiotoxicity. The mechanism of doxorubicin-induced cardiotoxicity may involve various signalling pathways including free radical generation, peroxynitrite formation, calcium overloading, mitochondrial dysfunction and alteration in apoptosis and autophagy. Interestingly, the use of resveratrol in combination with doxorubicin has been reported to prevent cardiac toxicity as well as to exert a synergistic effect against tumour cells both in vivo and in vitro. Thus, the aim of this review is to summarize current knowledge and to elucidate the protective effect of resveratrol in doxorubicin-induced cardiotoxicity.

[Carcinochemotherapy in pediatric surgery (author's transl)].

Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron

Cardioprotective Effects of Glycyrrhiza Uralensis Extract Against Doxorubicin-Induced Toxicity.

Ginsenoside Rh2 mitigates doxorubicin-induced cardiotoxicity by inhibiting apoptotic and inflammatory damage and weakening pathological remodelling in breast cancer-bearing mice

Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviating toxicity

Enhanced therapeutic efficacy of doxorubicin against multidrug-resistant breast cancer with reduced cardiotoxicity

Ginsenoside Rg2 Attenuates Doxorubicin-induced Cardiomyocyte Apoptosis via the PI3K/Akt Pathway

Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy

An orally administered bacterial membrane protein nanodrug ameliorates doxorubicin cardiotoxicity through alleviating impaired intestinal barrier

Targeting OGF/OGFR signal to mitigate doxorubicin-induced cardiotoxicity

A Novel Self-Assembly Albumin Nanocarrier for Reducing Doxorubicin-Mediated Cardiotoxicity.

Augmented gastric inhibitory polypeptide and insulin responses to a meal after an increase in carbohydrate (sucrose) intake.

AstragalusPolysaccharide Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the PI3k/Akt and P38mapk Pathways

Momordica charantia L.-derived exosome-like nanovesicles stabilize p62 expression to ameliorate doxorubicin cardiotoxicity

Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress

[Functioning adenomas of the adrenal cortex. Histological and ultrastructural aspects (author's transl)].

Functional exosomes modified with chitosan effectively alleviate anthracycline-induced cardiotoxicity

A Cardiac‐Targeting and Anchoring Bimetallic Cluster Nanozyme Alleviates Chemotherapy‐Induced Cardiac Ferroptosis and PANoptosis

Trophoblast Stem-Cell-Derived Exosomes Alleviate Cardiotoxicity of Doxorubicin via Improving Mfn2-Mediated Mitochondrial Fusion

Screening of renal artery stenosis: assessment with magnetic resonance angiography at 1.0 T.

Resveratrol, a Polyphenol Phytoalexin, Protects Against Doxorubicin‐induced Cardiotoxicity